Targeted Strategies for Today's Evolving Markets

MissionIR Blog

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Amir Reichman Featured on IBN’s The Bell2Bell Podcast

  • Reichman discusses BiondVax’s 2023 achievements, including the development of innovative NanoAbs in collaboration with the Max Planck Institute targeting interleukin-17 (IL-17) targeting diseases such as psoriasis
  • Annual sales for current anti-interleukin-17 monoclonal antibodies now total about $7.5 billion annually – and BiondVax is positioned to penetrate this market with promising results

Investor Brand Network (“IBN”) recently announced the release of its latest episode of The Bell2Bell Podcast, featuring Amir Reichman, CEO of BiondVax Pharmaceuticals (NASDAQ: BVXV). The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries – like BiondVax’s innovative platform technology using alpaca-derived nanosized antibodies, known as Nanobodies (NanoAbs) ( These NanoAbs address infectious and autoimmune diseases with large unmet medical needs, such as COVID-19, psoriasis, psoriatic arthritis, asthma, and macular degeneration.

BiondVax, in collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), both in Germany, is developing a pipeline of innovative NanoAbs that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration, and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

This recent interview between podcast host Stuart Smith and Reichman is a follow-up from December 2022 – beginning with BiondVax’s recent achievements, as detailed in a letter to shareholders issued late last year. Reichman told Smith that the company successfully executed a round of financing at the end of 2022, raising about $8 million. BiondVax also in-licensed the next antibody from the Max Planck Institute – a NanoAb designed to target interleukin-17 (IL-17) for the treatment of psoriasis, HS, and other important indications. BiondVax is now fast on the trail of developing what could be a very promising drug.

Autoimmune diseases are often chronic and require patients to take drugs for life, with annual sales for current anti-interleukin-17 monoclonal antibodies totaling about $7.5 billion. With their NanoAbs, BiondVax aims to generate a highly potent, highly specific drug that is safe to use for the large and underserved population of mild-to-moderate psoriasis patients. BiondVax expects to complete a proof-of-concept trial later this year, followed by human clinical trials.

Reichman explained that there are currently several treatment options on the market for psoriasis patients, such as, for example, creams and other topical drugs, biologics, and oral drugs for plaque psoriasis patients. However, the topicals are not highly sophisticated drugs, and they come with considerable side effects. “When a person needs to take steroids once in a while for an infection, they can tolerate it, but when you need to take steroids for an autoimmune disease with chronic inflammation, you create tolerance and deal with potential side effects,” the BiondVax CEO explained.

As for biologics, they are highly potent, but they are restricted to moderate and severe cases of psoriasis, which accounts for only 15% of patients with psoriasis. “The 85% that are left have to choose between drugs based on 1960s and 1970s technology. There hasn’t been much breakthrough in recent years to serve these patients,” Reichman added.

Additionally, BiondVax has also begun to offer contract development and manufacturing organization (“CDMO”) services. The CDMO services were designed to keep the BiondVax team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s primary focus – its potentially blockbuster NanoAb pipeline.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all

This entry was posted in BiondVax Pharmaceuticals Ltd. BVXV. Bookmark the permalink.

Comments are closed.